Table 1. Baseline Patient Demographic and Clinical Characteristics for Evaluable Patients.
| Characteristic | Patients, No. (%) |
|---|---|
| No. | 37 |
| Age, median (range), y | 34 (19-70) |
| Male | 12 (32) |
| Female | 25 (68) |
| Race and ethnicity | |
| African American | 6 (16) |
| Asian | 1 (3) |
| White | 26 (70) |
| Unknown or not reported | 4 (11) |
| Stage at initial diagnosis | |
| I or II | 17 (46) |
| III or IV | 14 (38) |
| Unknown | 6 (16) |
| Frontline therapy | |
| ABVD and AVD | 34 (92) |
| ABVD and GVDa | 1 (3) |
| ABVD and escBEACOPP | 1 (3) |
| ABVE PC and DECA × 2 | 1 (3) |
| Best response after frontline treatment | |
| Refractory (never with CR) | 16 (43) |
| Early relapse (CR <1 y) | 12 (32) |
| Relapse (CR >1 y) | 9 (24) |
| Ann Arbor stage at enrollment | |
| I or II | 16 (43) |
| III or IV | 21 (57) |
| Bulky disease (>10 cm) | 6 (16) |
| Received third cycle of PEM + ICE (optional) | 5 (14) |
| AHSCT conditioning regimen | |
| No. | 35 |
| BEAM | 25 (71) |
| CCE + TLI | 6 (17) |
| BCV | 3 (9) |
| CyVP + TBI | 1 (3) |
| Radiation therapy | |
| No. | 35 |
| Treatment with AHSCT conditioning | 7 (20) |
| Post-AHSCT consolidation | 4 (11) |
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; AHSCT, autologous hematopoietic stem cell transplant; AVD, doxorubicin, vinblastine, and dacarbazine; BCV, busulfan, cyclophosphamide, and etoposide; BEAM, carmustine, etoposide, cytarabine, and melphalan; CCE, carboplatin, cyclophosphamide, and etoposide; CR, complete response; CyVP, cyclophosphamide and etoposide; DECA, dexamethasone, etoposide, cytarabine, and cisplatin; escBEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; GVD, gemcitabine, vinorelbine, and doxorubicin liposomal; ICE, ifosfamide, carboplatin, and etoposide; PEM, pembrolizumab; TBI, total body irradiation; TLI, total lymphoid irradiation.
The only patient to receive 2 lines of therapy before enrollment.